Pulmatrix (PULM) Competitors $6.13 -0.31 (-4.81%) As of 05/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PULM vs. PLRX, TIL, XBIT, SAVA, GALT, VIRI, LXEO, VTYX, ANIX, and SNTIShould you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Pliant Therapeutics (PLRX), Instil Bio (TIL), XBiotech (XBIT), Cassava Sciences (SAVA), Galectin Therapeutics (GALT), Virios Therapeutics (VIRI), Lexeo Therapeutics (LXEO), Ventyx Biosciences (VTYX), Anixa Biosciences (ANIX), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry. Pulmatrix vs. Pliant Therapeutics Instil Bio XBiotech Cassava Sciences Galectin Therapeutics Virios Therapeutics Lexeo Therapeutics Ventyx Biosciences Anixa Biosciences Senti Biosciences Pliant Therapeutics (NASDAQ:PLRX) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability. Do analysts recommend PLRX or PULM? Pliant Therapeutics currently has a consensus price target of $13.31, indicating a potential upside of 900.94%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Pulmatrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Pulmatrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in PLRX or PULM? 97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by insiders. Comparatively, 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is PLRX or PULM more profitable? Pliant Therapeutics has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Pulmatrix's return on equity of -45.97% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -48.91% -41.09% Pulmatrix -96.51%-45.97%-30.72% Does the MarketBeat Community prefer PLRX or PULM? Pulmatrix received 120 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. However, 63.87% of users gave Pliant Therapeutics an outperform vote while only 48.04% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformPliant TherapeuticsOutperform Votes7663.87% Underperform Votes4336.13% PulmatrixOutperform Votes19648.04% Underperform Votes21251.96% Which has more risk and volatility, PLRX or PULM? Pliant Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Which has better earnings and valuation, PLRX or PULM? Pulmatrix has higher revenue and earnings than Pliant Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M51.67-$161.34M-$3.61-0.37Pulmatrix$7.81M2.87-$14.12M-$3.34-1.84 Does the media favor PLRX or PULM? In the previous week, Pulmatrix had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 5 mentions for Pulmatrix and 3 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.77 beat Pulmatrix's score of -0.04 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pulmatrix 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPliant Therapeutics beats Pulmatrix on 10 of the 17 factors compared between the two stocks. Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PULM vs. The Competition Export to ExcelMetricPulmatrixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.37M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-2.328.9226.7719.71Price / Sales2.87253.80393.17117.39Price / CashN/A65.8538.2534.62Price / Book1.246.466.794.50Net Income-$14.12M$143.98M$3.23B$248.18M7 Day Performance-5.98%2.03%1.53%0.20%1 Month Performance-2.85%4.11%10.06%12.37%1 Year Performance212.76%-2.87%16.74%7.04% Pulmatrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PULMPulmatrix0.3673 of 5 stars$6.13-4.8%N/A+206.5%$22.37M$7.81M-2.3220Earnings ReportAnalyst ForecastGap UpPLRXPliant Therapeutics4.3244 of 5 stars$1.47+4.3%$13.31+805.6%-90.9%$90.24M$1.58M-0.4490News CoveragePositive NewsGap DownTILInstil Bio2.2194 of 5 stars$13.68+3.4%$114.00+733.3%+45.2%$89.73MN/A-1.18410Gap DownXBITXBiotech0.6102 of 5 stars$2.91+5.1%N/A-67.2%$88.72M$4.01M-2.69100Positive NewsGap UpSAVACassava Sciences3.8157 of 5 stars$1.83+3.4%$54.50+2,878.1%-90.8%$88.40MN/A-1.3330GALTGalectin Therapeutics1.2204 of 5 stars$1.39+0.7%$11.00+691.4%-60.4%$87.82MN/A-1.909Earnings ReportGap UpVIRIVirios TherapeuticsN/A$4.56flat$3.00-34.2%+2,875.0%$87.82MN/A-16.895LXEOLexeo Therapeutics2.8394 of 5 stars$2.63-2.2%$22.20+744.1%-79.6%$87.31M$650,000.00-0.8358News CoverageAnalyst RevisionGap DownHigh Trading VolumeVTYXVentyx Biosciences2.2772 of 5 stars$1.21-2.4%$10.00+726.4%-67.7%$86.11MN/A-0.5130News CoveragePositive NewsGap UpANIXAnixa Biosciences1.7167 of 5 stars$2.66+1.9%$9.00+238.3%-6.2%$85.64M$210,000.00-6.825Gap UpSNTISenti Biosciences1.6894 of 5 stars$3.26flat$12.00+268.1%-14.7%$85.02M$2.56M-0.214 Related Companies and Tools Related Companies Pliant Therapeutics Alternatives Instil Bio Alternatives XBiotech Alternatives Cassava Sciences Alternatives Galectin Therapeutics Alternatives Virios Therapeutics Alternatives Lexeo Therapeutics Alternatives Ventyx Biosciences Alternatives Anixa Biosciences Alternatives Senti Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PULM) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PULM Stock Free PULM Stock Alerts